XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with ...

Around 20% of these centres have expanded their footprint across three or more cities, signalling a trend towards multi-city ...

Several drugmakers, including Eli Lilly, Johnson & Johnson ... Analysts and industry executives have said any new manufacturing facility could take at least five years to begin production.

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... threats are hindering further US investments in R&D and manufacturing. CNBC reported that, according to ...

Merck Animal Health and Eli Lilly and Company have individually ... along with $35 million to enhance R&D efforts focused on parasiticides and novel therapeutics. Construction on the ...

Mike Braun and Eli Lilly ... said the Lilly Medicine Foundry, the largest project announced for the LEAP District, will support about 400 jobs when it is completed in 2027. The facility will ...

Roche projected that its $50 billion manufacturing investment, to include research and development (R&D) operations ... 5,000 construction jobs. • Eli Lilly said it will spend $27 billion ...

Novartis has announced a $23 billion investment over five years to expand US-based manufacturing and R&D, aiming to produce 100% of its key ... the Novartis announcement follows similar moves from Eli ...

"Typically, that will be in reduction of staff or research and development, and I predict R&D will come first. That's a disappointing outcome." Eli Lilly has led the industry in building up its U ...

The boss of US pharmaceutical giant Eli Lilly has told the BBC there is no ... be in reduction of staff or research and development (R&D) and I predict R&D will come first. That's a disappointing ...